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I. Introduction
S ERINE PROTEINASES CONSTITUTE a family of proteolytic enzymes characterized by a unique catalytic triad consisting of Ser, His, and Asp. These residues are able to hydrolyze peptide bonds (1) . Serine proteinases are produced as inactive precursors or zymogens. Subsequent zymogen conversion into a mature physiologically active enzyme is mediated via a process called "limited proteolysis" or zymogen activation (2) (3) (4) . In mammals, serine proteases, for example, regulate the hemostatic and fibrinolytic balance, degrade neuropeptides involved in neurogenic inflamma-signal transduction pathways (see Sections II.H, III.H, and IV.B; also see Table 2 and Fig. 2 , and Refs. 13, 14, and 16) . Thus, PARs are not activated like "classical" receptors because the specific receptor-activating ligand is part of the receptor, whereas the circulating agonist is a relatively nonspecific serine proteinase that does not behave like a traditional hormonal regulator akin to insulin.
Several studies during the past few years have also demonstrated that several mechanisms exist to regulate stimulation and termination of PAR-initiated signaling (13) (14) (15) (16) 30) . Importantly, the availability of PARs at the cell surface is governed by trafficking of the receptor from intracellular stores, and the signaling properties depend on the presence of G proteins and G protein-coupled receptor kinases (GRKs) that modify activity. For PAR 1 , PAR 2 , and PAR 4 , it is well established that short synthetic peptides [PAR-activating peptides (PAR-APs)] designed on their proteolytically revealed tethered ligand sequences can serve as selective receptor agonists (Table 1) . Some PAR-APs activate more than one PAR, and they activate receptors at concentrations in the micromolar range as compared with nanomolar potencies of the proteinases themselves (31, 32) . Although the PAR 1 -AP, SFLLRN-NH 2 also activates PAR 2 , PAR 2 -APs, like SLIGRL-NH 2 are not capable of activating other PARs. Unfortunately, the relatively low potency (10 to 100 m EC 50 ) and susceptibility to aminopeptidases (33) limit the utility of the PAR-APs in some bioassay systems. Recently, modified synthetic agonist peptides with higher potency, resistance to aminopeptidases, and greater receptor selectivity have been developed and characterized. These receptor-selective agonists are of use to study the consequences of activating PARs in vivo (Table 1) (13, 14, 16, 34) . So far, antagonists 2 . PAR 3 , as will be elaborated upon in Section IV, remains a puzzle, in that studies with the murine receptor indicate that it cannot be activated either by its cognate synthetic tethered ligand peptide or by thrombin (39, 40) . Rather than acting as an independent cell regulator, PAR 3 appears to function as a cofactor for the activation of PAR 4 (39). Complementary data documenting PAR-mediated effects in various tissues have been obtained using PAR-deficient (PAR Ϫ/Ϫ ) mice. Taken together, data obtained using the enzyme activators themselves (trypsin, thrombin), the PAR-APs and using PAR gene-deficient mice provide compelling evidence that PARs play a critical role in the regulation of various physiological and pathophysiological functions in mammals, including humans. This review focuses on the biology and signaling properties of PARs in various mammalian tissues and highlights the current knowledge about the role of PARs during inflammation and immune response. To complement the information summarized in the sections that follow, the reader is encouraged to consult a number of other recent reviews concerning the activation mechanisms and cell biological aspects of PARs (13, 14, 16, 34, 41-45).
II. PAR 1 in Inflammation and Immune Response
Thrombin is an important effector proteinase of the coagulation cascade that leads to formation of a hemostatic plug. Thrombin is thought to act near the site at which it is generated and it is activated when circulating coagulation factors in the blood plasma make contact with tissue factor. Tissue factor is a membrane protein that is usually produced by cells that are separated from blood (i.e., epithelial cells). However, it is also expressed at low levels on circulating monocytes and microparticles from leukocytes. Tissue factor is associated with the activation of zymogen factor X by factor VIIa. Factor Xa together with its cofactor Va subsequently converts prothrombin to the active enzyme. Thus, plasma coagulation can only take place when the vascular integrity is damaged (15) . Thrombin causes shape change of endothelial cells and increased permeability of endothelial cell layers.
However, recent evidence revealed that thrombin is not only a clotting proteinase serving as both a pro-and anticoagulant molecule but also appears to play multifunctional roles related to inflammation, allergy, tumor growth, metastasis, tissue remodeling, thrombosis, and probably wound healing (13, 15, 42, 43) . Subsequent to the cloning of PAR 1 (17, 46) , it was realized that many of the cellular actions of throm- Asfaha et al. (197) Kawabata et al. (198) Nervous system (rat) Sensory nerves Plasma extravasation, edema, SP (236) bin (e.g., platelet aggregation, angiogenesis, endothelial cell permeability, vasoregulation, gene regulation, leukocyte trafficking, immunomodulation) could be attributed to the activation of its GPCR (40, (47) (48) (49) (50) (51) (52) (53) (17, 54, 58 -61) . A receptor with high affinity for thrombin has also been detected in rat peritoneal (15, 42) . A number of studies have revealed that thrombin and other agonists of PAR 1 can affect the vascular tone. For example, before the discovery of PAR 1 , it was observed that thrombin can regulate vascular tone by an endothelialdependent mechanism involving the release of nitric oxide (NO) (64). It is now recognized that this effect of thrombin is due to the activation of PAR 1 . Moreover, thrombin and PAR 1 agonists can contract vascular SMC (VSMC) by a direct effect that requires extracellular Ca 2ϩ (64). Thus, in isolated coronary artery and aorta preparations, PAR 1 mediates relaxation (64, 65). In contrast, PAR 1 agonists contract human placental and umbilical arteries (66). Furthermore, PAR 1 mediates prostanoid generation and secretion, cellular contraction and barrier dysfunction, and enhanced expression of platelet-derived growth factor (PDGF) in human and bovine endothelial cells (67). Interestingly, progestins such as progesterone or gestodene up-regulate PAR 1 expression and thereby stimulate thrombin-induced tissue factor-dependent surface procoagulant activity in the rat vascular system, suggesting a role of thrombin in hormone-induced thrombosis via PAR 1 activation (68). Recent observations support a role of thrombin and PAR 1 in regulation of functions normal (69 -71, 73) and atherosclerotic (75) endothelium. In normal human arteries, PAR 1 is mostly confined to the endothelium, whereas during atherogenesis, its expression is enhanced in regions of inflammation associated with macrophage influx, smooth muscle cell proliferation, and an increase in mesenchymallike intimal cells (75) . In vivo, a neutralizing antibody to PAR 1 has been observed to reduce expression of mRNA for the proliferating cell nuclear antigen, an index of intimal and Table 2 ).
neointimal smooth muscle cell accumulation in rat arteries during balloon angioplasty. These data suggest that PAR 1 regulates proliferation and accumulation of neointimal SMC during tissue repair (76).
Thrombin and PAR 1 agonists cause a rapid but transient contraction of endothelial cells in various tissues resulting in gap formation and increased permeability of plasma proteins and inflammatory cells. Several mediators are involved in this PAR 1 modulated process such as cytokines, kinins, and biogenic amines (67, 72, 77-95).
It was also revealed that PAR 1 plays a crucial role during vascular ontogenesis. Interestingly, about 50% of the PAR 1 -deficient mouse embryos die at midgestation with bleeding from multiple sites. However, a PAR 1 transgene driven by an endothelial-specific promoter prevented death of PAR 1 -deficient embryos (96) , indicating that PAR 1 modulates endothelial cell function in developing blood vessels, thereby contributing to vascular development and homeostasis in mice (88, 96) .
Vascular wall cells respond to the procoagulant factor Xa by an increase in intracellular Ca 2ϩ ([Ca 2ϩ ] i ) and by assembly of this factor into prothrombinase complexes that even enhance this effect. Additionally, factor Xa stimulation of PAR 1 leads to an increased production of tissue factor, a prothrombotic agent, underlining the important role of PAR 1 for thrombosis (86). Together, these results point to a pivotal role of PAR 1 in vascular homeostasis and thrombosis.
PAR 1 agonists are also mitogenic, stimulating proliferation of endothelial cells (97, 98) , mediating endotheliumdependent relaxation to thrombin and trypsin in human pulmonary arteries (99) , and causing the release of IL-6 from human microvascular endothelial cells (HMEC) (72). Because PAR 1 up-regulates ␣1(I)-procollagen synthesis in VSMC, one may speculate that PAR 1 plays a role in vascular wound healing (100) .
Finally, factors that regulate PAR 1 function on endothelial cells have also been studied. For example, PAR 1 is downregulated by shear stress (101) and inflammatory mediators such as TNF-␣ (102), and is directly modulated by thrombomodulin (103) in human endothelial cells. On the other hand, cyclic mechanical stress leads to an up-regulation of PAR 1 in VSMC (104) . In contrast to PAR 2 , little is known about the inflammatory mediators that regulate PAR 1 expression in unstimulated or stimulated endothelial cells.
As of yet, only a few studies exist about the role of GRKs in regulating PAR 1 in endothelial cells. Only recently, Tiruppathi et al. (105) found a crucial role of the isoform GRK-5 on thrombin-induced desensitization of PAR 1 .
It is also necessary to mention the recently demonstrated role of PAR 1 in vascular associated pathological processes in which thrombin is involved. The role of PAR 1 in thrombus formation was recently investigated in an animal model. Cook et al. (106) examined the role of PAR 1 in intravascular thrombus formation in an experimental model of arterial thrombosis in the African green monkey. Using a blocking antibody to PAR 1 , this group demonstrated a dramatically diminished thrombin-stimulated aggregation and secretion of human platelets, whereas platelet activation induced by the PAR 1 agonist SFLLR-NH 2 was not affected. These results demonstrated that a specific blockade of PAR 1 activation by thrombin can prevent arterial thrombosis in this animal model without significantly altering hemostatic parameters. The data suggest that PAR 1 is crucially involved in this disease and is an attractive antithrombotic therapeutic target, although it probably has to be inhibited in concert with the low-affinity thrombin receptor PAR 4 
to fully prevent platelet activation (see Section II.A).
A demonstrated role of PAR 1 in intravascular thrombus formation and knowledge about side effects of thrombin inhibitors made appealing an idea to investigate the potency of PAR 1 antagonists as antithrombotic therapeutic drugs. Indirect thrombin inhibitors like heparin and warfarin, which prevent the circulation of thrombin, or the newly developed direct thrombin inhibitor ximelagatran (465) are currently used for the treatment of cardiovascular diseases, e.g., myocardial infarction, atherosclerosis, and thrombosis. However, they carry potential bleeding liabilities as an undesirable side effect when administered in chronic patients. Because it is now well known that human platelet responses to thrombin are mainly mediated via PAR 1 (19) , direct inhibition of this receptor instead of the proteinase represents an attractive way to circumvent possible side effects by thrombin inhibitors.
PAR 1 possesses several extra-and intracellular sites that are crucial for its function and that might represent possible targets for antagonists (107) . On the extracellular side, blocking of the cleavage site or the hirudin-like domain could inhibit N-terminal cleavage. Bradykinin or peptides derived thereof, also known as thrombostatins, have been shown to prevent thrombin-induced platelet aggregation (108) . In addition, antibodies directed against both the cleavage site and the hirudin-binding site have been generated (106, 109) . Binding of the antagonist to either the tethered ligand or extracellular loop 2 prevents interaction of the novel N terminus with the extracellular loop. Several small synthetic antagonists have been developed that block the binding site of the tethered ligand. However, peptide antagonists based on modifications of the tethered ligand were relatively unstable or showed only limited inhibitory activity (35). Thus, a second generation of indole or indazole-based peptidemimetic antagonists was created that block binding of both the tethered ligand and the proteinase (110) . One of these was recently shown to prevent thrombus formation in nonhuman primates (107) . In addition, several nonpeptide inhibitors were developed. However, it was not reported whether these compounds were PAR 1 -specific (111) . On the intracellular side, the G protein binding sites are possible targets for pharmacological intervention. One approach used the transfection of endothelial cells with a G␣ minigene (112). However, this might suppress all signaling pathways that involve G␣. Another more specific approach used so-called "pepducins," peptides that were derived from the third intracellular loop of PAR 1 . These peptides were able to permeate the cells and also carried a membrane anchor (113, 114).
In summary, two preclinical studies with primates demonstrated that PAR 1 antagonists have indeed a therapeutic potential for the treatment of cardiovascular diseases (106, 107) . However, extensive research needs to be done for the development of orally administered PAR 1 antagonists be-cause only those drugs are thought to be suitable for chronic patients (111) .
B. Platelets
Activation of platelets by thrombin or APs specific for PAR 1 is characterized by calcium influx; cytoskeletal reorganization; platelet aggregation; degranulation (17, 115, 116) ; thromboxane production (117); mobilization of the adhesion molecule P-selectin and the CD40 ligand to the platelet surface (119); stimulation of serotonin and epinephrine release (120); enhanced expression of CD62, PDGF (AB) and PDG-F(BB) (121); and exposure of anionic phospholipids (phosphatidylserine, phosphatidylethanolamine) that support blood clotting (122). Thrombin has also been demonstrated to stimulate vascular endothelial growth factor release in megakaryocytes and platelets (123). The growth factor in turn is able to induce proliferation of endothelial cells. In addition, tissue inhibitor of matrix metalloproteinase (MMP)-4 that colocalized with MMP-2 in resting platelets was released upon platelet aggregation induced by collagen and thrombin. However, a direct effect using specific PAR 1 agonists has not been shown yet (124). The density of human PAR 1 on the platelet cell surface was estimated to be about 1500 molecules per resting platelet (125). A recently reported intronic polymorphism in the PAR 1 gene leads to decreased expression on the platelet surface and thus to a lower response to the AP (126, 127). PAR 1 is a high-affinity thrombin receptor in humans: receptor blocking using an antagonist, domain specific antibodies, or simply by desensitization led to inhibition of responses at 1 nm thrombin but only to attenuated responses at 30 nm (128).
High-affinity thrombin binding of platelets is possibly associated via the membrane glycoprotein (GP)Ib-IX-V complex. This interaction is lost in patients suffering from the Bernard-Soulier syndrome, a disease where GPIb-IX-V is not expressed (129). The same condition can be mimicked using either monoclonal antibodies directed against GPIb or proteolytic removal of this protein from the platelet surface (130). Under these conditions, platelet aggregation is either delayed or requires higher thrombin concentrations.
Recently, Schmidt et al. (131) reported that the gene encoding IQ motif containing GTPase activating protein-2, a scaffolding protein for filopodal extension during platelet activation, was identified within the human PAR gene cluster at 5q13, flanked by the PAR1 gene and encompassing the PAR3 gene. Only thrombin-or PAR 1 -AP-activated platelets showed a rapid translocation of IQ motif containing GTPase activating protein-2 to the platelet cytoskeleton. This suggests that a functional genomic unit evolved to mediate thrombin signaling events in humans (132).
PAR 1 on platelets also seems to play an important role during bacterial invasion: the cysteine proteinase gingipain from Porphyromonas gingivalis was reported to activate the receptor leading to uncontrolled activation of the host cells (28) . The enzyme streptokinase derived from Streptococcus sp. is widely used in the treatment of coronary thrombosis. It functions as a plasminogen activator that forms an active complex with plasminogen of the host that is able to cleave PAR 1 (133). In mouse platelets, PAR 1 does not seem to play a role: PAR 1 expression was hardly detectable, and a specific AP did not activate rodent platelets (23, 134, 135) . Moreover, platelets derived from PAR 1 -deficient mice responded to thrombin-like wild-type platelets (135).
C. Immune cells
For some time, an important role for serine proteinases and PARs for the modulation of leukocyte effector functions has been proposed (136). As of yet, only limited data about the regulation of immune and inflammatory responses by PARs are available. It is well documented that PARs influence monocyte motility and chemotaxis, modulate pleiotropic cytokine responses, contribute to mononuclear cell proliferation, and induce apoptosis in various immune cells (84, 137). Recently, it was shown that PAR 1 is capable of stimulating elastase secretion from macrophages (138). Moreover, functional thrombin receptors are expressed on human T lymphoblastoid cells (139). However, the receptor subtype(s) (PAR 1 , PAR 3 , and PAR 4 ) have not been characterized as of yet. Human ␣-thrombin stimulated five different T lymphoblastoid cell lines to increase intracellular free Ca 2ϩ concentrations and to activate protein kinase C (PKC), whereas thrombin receptors were absent in B cell lines. Thus, PARs may regulate T cell function during inflammation and immune responses, but the precise mechanism is still unknown. Granzyme A from cytotoxic and helper T lymphocytes appears to interact with PAR 1 in astrocytes to regulate thrombin function (140). Interestingly, granzyme A blocked the thrombin-induced platelet aggregation in a dose-dependent manner by cleaving PAR 1 , presumably downstream from its thrombin targeted activation site, thereby reducing the response to subsequent challenge with thrombin; but granzyme A itself did not induce a signal in thrombin-stimulated platelets. Thus, granzyme A may interact with PAR 1 in a manner that is insufficient to cause aggregation, but sufficient to disarm the ability of the receptor to respond to thrombin. Finally, these observations demonstrate that granzyme A release occurring during immune responses within blood vessels would not directly cause platelet aggregation. Thus, the T cell-derived proteinase granzyme A seems to inhibit responses triggered by thrombin during inflammation or tissue injury.
PAR 1 modulates chemotaxis in inflammatory cells. Besides IL-8 secretion (71), thrombin induces production of monocyte chemoattractant protein-1 (MCP-1) in monocytes, probably via PAR 1 (58). However, other PAR 1 -specific agonists were not used in this study. Therefore, it cannot be excluded that other thrombin receptors are involved. IL-8 secretion is up-regulated by interferon-␥ (IFN-␥) and diminished by prostaglandin (PG)E 2 (51), suggesting a role in cytokine modulation. Furthermore, PAR 1 is capable of inducing IL-1 as well as IL-6 production in monocytes (82). These cytokines are known to be proangiogenic, implicating PAR 1 in angiogenesis and tissue repair. However, IFN-␥-differentiated growth-arrested U937 cells also respond to PAR 1 agonist administration by overcoming cell arrest and revert to a high proliferation rate via regulation of p21 CIP1/WAF1 and cyclin D 1 . Together, these results may help to explain how thrombin promotes tissue repair and unrestricted proliferation in malignant tissues (137, 141).
Because thrombin, via PAR 1 , is chemotactic for large granular lymphocytes in humans (55), large granular lymphocytes can enhance the effects of PAR 1 in patients with inflammatory disorders (142-144). Moreover, thrombin modulates activity of NK cells (48). For example, thrombin can enhance NK cell-mediated cytotoxicity and IL-2 production in rheumatoid arthritis, and PAR 1 may therefore play an important role in this inflammatory process, as well as in NK cell responsiveness to IL-2.
D. Airways
Various cells in mammalian airways such as epithelial cells, SMC, and fibroblasts abundantly express PAR 1 on the cell surface. Several recent studies also suggest that PAR 1 may play an important role in inflammatory lung diseases such as neutrophilic alveolitis, pulmonary fibrosis, and asthma (50, 77, 91, 145-149).
In the airways of different species, PAR 1 exerts a dual role leading to stimulation of contraction on the one hand and relaxation on the other hand. For example, thrombin stimulates contraction of human bronchial rings (150) and constriction in guinea pig bronchi (as does AP) (151), but activates constriction as well as relaxation in mouse tracheal SMC (152, 153). In these mouse studies, trypsin, thrombin, and peptide agonists of PAR 1 , PAR 2 , and PAR 4 induced relaxant responses of isolated tracheal smooth muscle preparations, which were mediated by a prostanoid, probably PGE 2 . This effect was abolished by indomethacin, the cyclooxygenase (COX)-2 inhibitor, nimesulide, and a prostanoid receptor antagonist (AH6809). PAR 1 and PAR 4 synthetic peptides induced a rapid, transient, contractile response that preceded the relaxant response. Interestingly, the relaxations but not the contractions were inhibited by indomethacin, indicating that this response is mediated by cyclooxygenase products.
E. Gastrointestinal tract
PAR 1 was detected in the lamina propria, the submucosa, endothelial cells, and nerves of the gastrointestinal (GI) tract (154 -157). The GI tract expresses relatively high levels of PAR 1 mRNA compared with other tissues, both in mice and humans. The functional role of PAR 1 as a receptor mediating thrombin-induced effects in the GI tract is far from being resolved because thrombin can also interact with PAR 3 and PAR 4 (18, 20, 74 
F. Kidneys and urogenital tract
Recently, a crucial role of PAR 1 in the cell-mediated renal inflammation of crescentic glomerulonephritis has been demonstrated in vivo (49). In wild-type mice treated with hirudin (a direct thrombin inhibitor, characterized by a bifunctional mechanism of inhibition, exclusive specificity and strong ability to bind the enzyme) and in PAR 1 -deficient animals, the proinflammatory effect of thrombin was significantly reduced. Moreover, treatment of wild-type mice with the PAR 1 peptide agonist (SFLLRN-NH 2 ) augmented the inflammatory response, suggesting that PAR 1 plays an important role in renal inflammation in vivo. Unfortunately, as mentioned above, the peptide SFLLRN-NH 2 can also activate PAR 2 with a comparable potency, and therefore a role of PAR 2 in renal inflammation cannot be ruled out by this study. Surprisingly, although highly expressed in human kidneys, data clarifying a role for PAR 1 in inflammation of human kidneys are still lacking.
Recent data revealed that PAR 1 is involved in cellular invasion of a transfected canine kidney cell line. PAR 1 agonists abrogated G␣ (olf) -mediated invasion of MDCKts.src cells in collagen gels, indicating an important role for PAR 1 in tumor metastasis (168, 169). Using the human urogenital cell line RT4, studies done in vitro have revealed that PAR 1 and PAR 2 agonists are capable of activating iPLA 2 accompanied by release of PGE 2 , which may provide cytoprotection during an acute inflammatory reaction (170).
G. Brain and peripheral nervous system
Recent studies are in favor of an important role of thrombin and PARs in the brain under normal and pathophysiological conditions such as trauma, inflammation, or tumorigenesis (171, 172). Under pathophysiological conditions, i.e., during breakdown of the blood-brain barrier, circulating thrombin in the bloodstream may enter the central nervous system (CNS), leading to activation of PAR 1 or PAR 4 . Additionally, neurons and glia cells are capable of generating prothrombin (173). Most data so far have been achieved by investigating PAR 1 (13, 14, 174) . In rat brain, PAR 1 is expressed by neurons of the neocortex, cingulate cortex, subsets of thalamic and hypothalamic nuclei, discrete layers of the hippocampus, cerebellum, and olfactory bulb, as well as by astroglia (60). Striggow et al. (175) showed that all four PAR subtypes are expressed in rat brain. PAR 1 expression was most abundant in the hippocampus, amygdala, and cortex. Interestingly, the expression of PAR 1 , PAR 2 , and PAR 3 was up-regulated during experimentally induced ischemia.
In human brain, PAR 1 is expressed in neurons and astrocytes (175). Cultured rat glia cells (C6) express both functional PAR 1 and PAR 2 (176, 177). Moreover, PAR 1 agonists induce up-regulation of inducible NO synthase (iNOS) in these cells (85) and promote neuronal survival after ischemia (178) or brain trauma (179). PAR 1 also protects astrocytes and neurons from apoptosis induced by hypoglycemia and oxidative stress during inflammation (180). In contrast, thrombin may also exert cytotoxic effects on neurons and induce neurite retraction (181, 182), which may be at least in part due to PAR 1 . Functional studies further revealed that PAR 1 agonists cause retraction of neurites by neuroblastoma cells (181) and induce Ca 2ϩ mobilization by hippocampal neurons (178). In astrocytes, thrombin stimulates aggregation, morphological changes, and proliferation via PAR 1 and induces intracellular caspase pathways leading to apoptosis in a cultured motor neuron cell line (NSC19) (183, 184). Both PAR 1 and PAR 2 stimulate enhanced proliferation of astrocytes (185). Friedmann et al. (186) reported a key role of thrombin in PAR 1 -mediated postinjury neuron survival. They demonstrated that the toxicity of thrombin on neurons can be controlled by down-regulation of PAR 1 and/or release of antithrombin III by T cells. Interestingly, prothrombin expression was enhanced 24 h after injury, whereas PAR 1 , PAR 3 , and nexin-1 mRNA expression was unchanged (187). Nexin-1 is a thrombin inhibitor that also appears to control thrombin-PAR 1 interactions in a rat trauma model (171, 187, 188). Thus, the whole factory needed to regulate and modulate thrombin function, including receptor as well as activating and inhibiting proteinases, can be generated in the brain. However, PAR 1 also induces the reversal of astrocyte stellation in mice and rat (189 -191) . A comparable process is caused by exogenous or endogenous injuries of the CNS, triggering astrogliosis.
Taken together, these data clearly indicate a functional role of PAR 1 during inflammation and injury in the CNS. However, in some studies using thrombin as an agonist, activation of other PARs and a role of other molecules like thrombomodulin cannot be excluded. For example, thrombin itself up-regulates thrombomodulin in astrocytes in a dosedependent manner (192) . Thus, future studies taking into account all CNS-derived PARs, their proteinases, and proteinase inhibitors are necessary to fully explore the role of PARs in the brain. Finally, some authors suggest a role of thrombin in Alzheimer's disease, amyotrophic lateral sclerosis, or HIV encephalitis, probably via activation of PARs (182, 193, 194) .
Accumulating data also indicate the role of PAR 1 in the peripheral nervous system. In rat peripheral nerves, PAR 1 is expressed by primary afferent neurons (195) . From these observations, one may speculate that thrombin may also regulate inflammatory responses in the peripheral nervous system via PAR 1 . Indeed, very recently it has been demonstrated that PAR 1 is expressed by a large proportion of primary spinal afferent neurons (155). Thus, thrombin directly signals to sensory neurons by cleaving PAR 1 . Moreover, administration of PAR 1 agonists can induce plasma extravasation and edema, which were blocked by ablation of sensory nerves and administration of antagonists to the neurokinin-1 receptor, supporting the idea that thrombin cleaves PAR 1 on sensory nerves to stimulate release of SP, which in turn interacts with the NK 1 receptor to induce neurogenic inflammation. Thus, thrombin triggers neurogenic inflammation via PAR 1 (155). However, because PAR 2 and PAR 4 mRNA are also expressed in the CNS, it cannot be excluded that proinflammatory effects of thrombin in the nervous system may, in addition, be mediated by other PARs. Functional studies further revealed that PAR 1 agonists induce Ca 2ϩ mobilization in enteric neurons, and regulate both excitatory and inhibitory neurons of the myenteric plexus in guinea pig small intestine, e.g., by releasing neuropeptides (196) .
Recently, Vergnolle and co-workers (197) as well as other groups (198) examined the effects of PAR 1 agonists on nociceptive responses to mechanical and thermal noxious stimuli. Interestingly, intraplantar injection of selective PAR 1 agonists induced an enhanced nociceptive threshold and withdrawal latency resulting in mechanical and thermal analgesia. However, thrombin was analgesic in response to mechanical, but not to thermal, stimuli. Moreover, application of PAR 1 -AP with carrageenan significantly reduced the hyperalgesia. Thus, thrombin may play a dual nociceptiveanalgesic role, and future studies will be required to determine whether PAR 1 agonists might be of therapeutic use for the treatment of pain.
H. Signaling by proteinases via PAR 1
Investigations during the last few years revealed that the above-mentioned PAR 1 -mediated effects are transduced by various signaling pathways leading to diverse functions of PAR 1 under physiological and pathophysiological conditions. These findings were recently reviewed (13) . However, in the current work we focus on the signaling events mediated via PAR 1 in different tissues and cell types ( Table 2 ).
1. Platelets. After its generation from prothrombin, thrombin plays multiple roles in the blood coagulation cascade that are mediated by interaction with a number of physiological substrates, effectors, and inhibitors. The accumulation of thrombin at sites of vascular injury provides the recruitment of platelets into a growing hemostatic plug. When added to human platelets in vitro, thrombin causes platelets to change shape, stick to each other, and secrete the contents of their storage granules. How this is accomplished is still not fully understood, but a major step forward occurred since the identification of PAR 1 in the 1990s. This finding shed light on the way by which an extracellular protease may initiate intracellular events.
Mammalian GTP-binding proteins (G proteins) fall into four families that are typically referred to by the designation of the ␣-subunit: G s , G i , G q/11 , and G 12/13 . Human platelets express at least one member of the G s family and four members of the G i family (G i1 , G i2 , G i3 , and G z ) , which, among other functions, stimulate or inhibit cAMP formation by adenylyl cyclase (199) . In addition, platelets express one or more members of the G q/11 family and members of the G 12/13 family (G 12 and G 13 ) (199) .
A number of different G protein ␣-subunits have been shown to bind to PAR 1 , including members of the G i , G q/11 and G 12/13 families (200) . However, the knowledge of these interactions in humans under physiological and pathophysiological conditions is still far from completion. Kim et al. (201) have demonstrated that thrombin and PAR 1 -AP, as well as PAR 4 -AP, induce G i pathway stimulation in human platelets. Additionally, the authors demonstrated that thrombin, PAR 1 -AP, and PAR 4 -AP cause platelet aggregation independently of G i stimulation (201) . Offermanns et al. (202) also demonstrated a direct interaction between G 12 , G 13 , and PAR 1 . Additionally, it was reported that thrombin-mediated cleavage of the PAR 1 (and PAR 4 ; see Section IV.B) receptor leads to calcium-dependent and calcium-independent shape changes of human platelets in consequence of direct activation of both G q and G 12/13 pathways, respectively (115, 202). Therefore, current evidence suggests that PAR 1 interacts with G q , G 12/13 , and possibly G i protein family members in human platelets. In turn, these data suggest an activation of downstream signaling cascade members after PAR 1 stimulation on human platelets. Among such members are phospholipase C (PLC)-␤, phosphoinositide 3 (PI3)-kinase, and monomeric G proteins.
Indeed, PI3 kinase was demonstrated to play an important role in some PAR 1 or thrombin-mediated cellular effects such as cytoskeletal reorganization, alterations in cell motility, cell survival, and mitogenesis. For example, thrombin is able to activate multiple PI3-kinase isoforms, including the recently discovered 110-kDa isoforms that can be directly activated by G protein ␤␥-subunits (145, 150, 203). Stimulation of platelets by PAR 1 leads to the activation of PI3 kinase, which is dependent on the small G protein Rho (204) . Recently, Trumel et al. (205) have demonstrated that PI3 kinase plays an important role in the PAR 1 -dependent reorganization of the platelet cytoskeleton via myosin heavy chain translocation and stable association of signaling complexes with the actin cytoskeleton. Interestingly, the activity of small G proteins such as Rac and cdc42 in platelets may be regulated through PAR 1 stimulation, but the role of PI3 kinase in these events remains to be determined (206) . In their recent study, Vaidyula and Rao (207) provided evidence that in human platelets PLC-␤2 plays a major role in responses to PAR 1 and PAR 4 activation, and that PLC-␤2 is required for the sustained rise in [Ca 2ϩ ] i concentration upon thrombin activation.
Putting all of this together, current data suggest that thrombin activates human platelets by cleaving and activating PAR 1 and PAR 4 . In turn, PAR 1 activates the members of G q/11 , G 12/13 , and perhaps G i families, leading to the activation of PI3 kinase, PLC-␤, and monomeric G proteins (Rho, Rac, and possibly RapI), and also causes an increase of cytosolic Ca 2ϩ concentration and inhibition of cAMP formation.
Additionally, it is important to note that despite the fact that human platelets express both PAR 1 and PAR 4 , these receptors appear to be activated by different thrombin concentrations. Cleavage of human PAR 4 requires a higher concentration of thrombin than does cleavage of PAR 1 , and it is likely that PAR 1 is the predominant signaling receptor at low thrombin concentrations (208, 209) .
Mouse platelets provide an interesting contrast to human platelets: whereas human platelets express functional PAR 1 and PAR 4 , mouse platelets express PAR 3 and PAR 4 , although in the latter case signaling appears to be mediated entirely by PAR 4 , with PAR 3 serving to facilitate PAR 4 cleavage at low thrombin concentrations (for details, see Section IV.A) (39, 40).
2. Cells in the nervous system. PAR 1 , as mentioned above, appears to affect various processes in both the central and peripheral nervous systems (45, 210). Among such processes are: neuroinflammation and neurodegeneration, neuritogenesis, astrocyte proliferation, and synaptic plasticity. However, here we would like to focus on data concerning the involvement of PAR 1 in intracellular signaling cascades in neuronal cells. PAR 1 may have an effect on various intracellular signaling cascades within neuronal cells (171, 181, 189). By coupling to different G proteins, PAR 1 affects a wide range of neuronal cell functions. For example, the necessity of PAR 1 coupling to G 12 was demonstrated for thrombin-stimulated DNA synthesis in 1321N1 astrocytoma cells (211) . Interestingly, injection of antibodies directed against G 12 abolished the thrombin-stimulated DNA synthesis (212) . Additional studies performed on 1321N1 astrocytoma cells revealed that thrombin treatment causes a concentration-dependent rounding. One may speculate that such an effect of thrombin could be Rho-dependent. The Rho family of small GTPases is known to be involved in the control of cytoskeletal changes via modulation of actin polymerization. Indeed, this thrombininduced rounding of 1321N1 astrocytoma cells was Rhodependent and mediated via G 12 (213) .
Moreover, LaMorte et al. (214) demonstrated binding of PAR 1 to G q by using the same cell line. The authors also showed that thrombin stimulation induces Ras-GTP complex formation and that Ras is required for PAR 1 -mediated activation of PLC in 1321N1 astrocytoma cells (214) . This is especially interesting because thrombin is known to be a factor regulating the proliferation of astrocytes. This effect of thrombin appears to be associated with G o/i -and G q -mediated pathways. Wang and coworkers recently shed some light on the downstream cascade events of PAR 1 signaling (174, 210). G q -Mediated PLC activity results in Ca 2ϩ mobilization and activation of PKC, which phosphorylates a nonreceptor tyrosine kinase, proline-rich tyrosine kinase (Pyk2). Interestingly, the activation of other nonreceptor tyrosine kinases like Src and focal adhesion kinase (FAK) was also demonstrated after thrombin stimulation. Pyk2 is a factor that is able to connect GPCRs to ERK1/2 activation. Therefore, Pyk2, acting together with Src-tyrosine kinase, causes the activation of the ERK/MAPK pathway, which mediates the proliferative effect of thrombin. Additionally, the same group of authors demonstrated that the G o/i -mediated PI3 kinase pathway is also involved in thrombin-induced astrocyte proliferation (174).
Thrombin is also known to exhibit both beneficial and unfavorable effects in hippocampal neurons and astrocytes (178, 180, 215). Donovan and colleagues (184, 216) found that tyrosine kinases, serine/threonine kinases, and the actin cytoskeleton are involved in both pro-and antiapoptotic effects of thrombin in neuronal cells. However, there was no involvement of G o/i and the PI3 kinase pathway observed in these thrombin effects.
Additionally, Zieger et al. (217) demonstrated the existence of a novel PAR 1 -associated signaling pathway in the nervous system. According to these data, PAR 1 participates in cAMPindependent PKA activation in SNB-19 glioblastoma cells. Moreover, PAR 1 stimulation causes the activation of transcriptional factor nuclear factor B (NFB) in this cell type (217) .
In summary, besides morphological and proliferative effects described above that are mediated via G 12/13 , G q , and G o/i , respectively, thrombin also affects activation of transcriptional factors such as activator protein-1 (AP-1) in neuronal cells (214) . After dissociation of the G protein heterodimer, G␤␥ interactions activate phosphoinositide 3-kinase, which promotes [Ca 2ϩ ] i release that is required for SMC growth in response to thrombin stimulation (223) .
It is also interesting that PAR 1 signaling can modulate gene transcription induced by cytokines in SMC. Thrombin, acting via PAR 1 , can block IL-6-induced signal transducer and activator of transcription 3/Sis-inducible factor-A (Stat3/SIF-A) activation (224) .
In summary, since the discovery of PARs, considerable progress in our understanding of thrombin signaling in SMC was achieved. This allowed some light to be shed on signaling events associated with SMC proliferation, migration, and synthesis of extracellular matrix proteins (e.g., collagen) after thrombin stimulation. However, additional studies are necessary to reveal the role of thrombin in SMC apoptosis, vascular lesion formation, and wound-healing associated pathways.
Endothelial cells.
Thrombin is known to affect various functions of endothelial cells. Among these are cell rounding, changes of cell-cell junctions, proliferation, barrier function, and permeability. These thrombin-induced effects appear to be mediated via PARs, particularly PAR 1 (225, 226) . A major step forward was reached in recent studies, which revealed important intracellular signaling events underlying PAR 1 -mediated effects in endothelial cells (227) .
PAR 1 was demonstrated to interact with G o/i , G q , and probably G 12/13 in endothelial cells (228, 229) . As well as it was demonstrated for neuronal cells, PAR 1 -mediated cytoskeletal changes in endothelial cells (cell rounding) are associated with the activation of RhoA (225) . Additionally, in the same work it was demonstrated that PAR 1 -AP stimulation rapidly enhanced vascular permeability in a mouse skin assay (225) . Moreover, it was found that binding of PAR 1 to pertussis toxin (PTX)-sensitive G proteins (however only to G o , but not to G i ) is also necessary for thrombin-induced changes of endothelial barrier permeability (229) . The activation of the MAPK signaling pathway by thrombin in endothelial cells was also demonstrated. This activation plays a crucial role in thrombin-induced effects of endothelial cell functions such as chemokine and cytokine production as well as the expression of cell adhesion molecules (89, 230, 231) .
The role of thrombin and PAR 1 in the activation of transcriptional factor networks was intensively investigated in recent publications. Malik and coauthors (228, 231, 232) studied the involvement of PAR 1 in the activation of NFB in endothelial cells. Their studies showed that G ␣q and the G ␤ ␥ dimer are responsible for NFB activation and intercellular adhesion molecule-1 (ICAM-1) transcription in endothelial cells induced by the PAR 1 agonist thrombin and the PAR 1 -specific AP TFLLRNPNDK. Furthermore, transfection experiments strongly supported simultaneous activation of G ␤ ␥/PKC-␦/p38 and G ␤ ␥/PI3-kinase pathways that converge into the Akt pathway, leading to subsequent NFB activation and ICAM-1 expression (228, 231, 232) . Moreover, thrombin-induced stimulation of vascular cell adhesion molecule-1 (VCAM-1) production involves the inducible binding of p65 NFB to a tandem NFB motif in the 5Ј flanking region (233) . Taken together, these findings suggest that in the case of ICAM-1 and VCAM-1, p65 NFB is necessary for transducing the thrombin response in endothelial cells.
Additionally, thrombin-mediated induction of VCAM-1 was shown to involve the inducible binding of GATA-2 to a tandem GATA motif in the upstream promoter region (234) . Interestingly, the effect of thrombin on GATA-2 DNA bind-ing and transcriptional activity was found to be mediated by a PI3K, PKC--dependent signaling pathway (233) .
It is important to note that thrombin effects on transcriptional factor networks have been more deeply investigated in endothelial cells than in other cell types. These data explain, at least in part, thrombin-mediated effects on the production of cell adhesion molecules and some chemokines in endothelial cells. Subsequently, this accounts for thrombin effects at leukocyte migration via endothelial barrier (ICAM-1 serves as a ligand for leukocyte ␤ 2 integrins and promotes leukocyte adhesion) and leukocyte recruitment. (237) . Tyrosine phosphorylation of Vav1 regulates its activity as a guanine-nucleotide exchange factor for the Rho-like small GTPases RhoA, Rac1, and cdc 42, which affect cytoskeletal reorganization and activation of stress-activated protein kinases/JNKs. Bar-Shavit et al. (236) clearly showed that activation of PARs induces tyrosine phosphorylation of Vav1 in Jurkat T-leukemic cells. Because -chain-associated protein kinase of 70 kDa (ZAP-70) and SH2-domain containing leukocyte-specific phosphoprotein of 76 kDa (SLP-76) have been shown to associate physically with Vav1 and because this association is critical for normal functioning of T cells, it was tempting to investigate whether ZAP-70 and SLP-76 are involved in PAR-induced signaling cascades. Indeed, an increase of tyrosine phosphorylation of ZAP-70 and SLP-76 was observed after activation of Jurkat cells with PAR-APs. Moreover, phosphorylation of Vav1 in response to PAR stimulation was dependent on p56 lck (236) . Unfortunately, because nonselective PAR-APs were used in the studies done with the Jurkat cells (236) , it is difficult to distinguish between the effects of PAR 1 and PAR 2 in this T cell model system. Furthermore, because of the lack of the ability of PAR 3 -derived peptides to activate PAR 3 (39), the role of PAR 3 in T cell signaling remains unknown. 1 . Most of the PAR 1 -associated signaling events have been observed subsequent to cell stimulation by thrombin. However, recently a possible role of PAR 1 in coagulation factor Xa-mediated signaling has been demonstrated (238 -240) . The coagulation proteinase factor Xa is generated at sites of vascular injury and inflammation after formation of the tissue factor/VIIa (TF/VIIa) complex. Coagulation factor Xa has been shown to be mitogenic for SMC (238) and elicits inflammatory responses in endothelial cells. Riewald and Ruf (241) have presented new data indicating the involvement of PAR 1 in Xa-mediated signaling. They used HeLa cells expressing only PAR 1 and demonstrated that factor Xa induces NFB activation and MAPK phosphorylation in these cells. Inhibition studies with specific antibodies revealed that factor Xa responses were mediated via PAR 1 (241) . Thus, factor Xa (or potentially other serine proteinases) may substitute for thrombin in proteolytic signaling via PAR activation. In endothelial cells, which also express PAR 2 , Camerer et al. (240) have shown that factor Xa signaling was mediated not only by PAR 1 , but also to a large extent via PAR 2 . Together, PAR-1 and PAR-2 appear to account for more than 90% of factor Xa signaling in endothelial cells (240) .
Factor Xa signaling mediated via PAR
In summary, the multiple biological as well as inflammatory and immune responses of thrombin that are mediated by PAR 1 [including 1) vasoregulation; 2) increased vascular permeability; 3) cellular adhesion and infiltration of leukocytes; 4) angiogenesis; 5) stimulation of the production of inflammatory mediators such as cytokines, neuropeptides, NO and prostanoids, for example; 6) regulation of extracellular matrix proteins; and 7) induction of signal transduction pathways which are involved in immunomodulation] suggest an important role of PAR 1 during inflammation and immune response.
III. PAR 2 in Inflammation and Immune Response
PAR 2 is expressed in brain, lia (DRG), eye, airway, heart, GI tract, pancreas, kidney, liver, prostate, ovary, testes, and skin (21-22, 24, 154, 242-245) and is found in various cell types such as epithelial cells, endothelial cells, SMC, osteoblasts, as well as immune cells such as T cells, neutrophils, mast cells, or eosinophils (97, 154, 246 -254) . On the other hand, platelets do not express PAR 2 (248) . Recent findings point to an important role for PAR 2 under physiological and pathophysiological conditions in many tissues (Table 2) . However, the endogenous enzymes responsible for activating PAR 2 in many tissues remain to be determined. Many endogenous or exogenous trypsin-like enzymes may cleave and activate PAR 2 . Expression of trypsinogen-2 mRNA and its translation product has been demonstrated in endothelial cells (255) . Interestingly, various types of human cancer cells secrete enzymes with trypsin-like specificity (255) that may activate PAR 2 . In human skin, trypsinogen-4 generated by keratinocytes and trypsinogen-2 from human dermal microvascular endothelial cells can activate PAR 2 in vitro (M. Steinhoff, unpublished observation). Another candidate is mast cell tryptase, a major secretory protein of human mast cells. Mast cells from mice and rats are more heterogeneous regarding their protease content, although they also produce proteases with tryptic specificity. Tryptase has been shown to activate PAR 2 on epithelial as well as endothelial cells and neurons (23, 196, 243, 251, 256) . The observation that tryptase can activate PAR 2 suggests a role of this receptor in humans under circumstances when mast cells are involved, e.g., during inflammation, hypersensitivity reactions, and wound repair (24, 257) . However, the ability of human tryptase to activate PAR 2 appears to be restricted by receptor glycosylation at an N-terminal residue just proximal to the receptor's cleavage activation site (258, 259) . Notwithstanding, the effects of tryptase on cells in vitro often mimic those of PAR 2 activation: tryptase up-regulates IL-1␤ and IL-8 secretion, enhances the presence of intracellular adhesion molecules/ selectins on endothelial cells, mediates accumulation of neutrophils and eosinophils, produces vascular leakage, and is mitogenic for epithelial cells, fibroblasts, and SMC (260 -263) . That said, direct proof that PAR 2 mediates the effects of tryptase during inflammation in vivo is still lacking.
A. Vasculature
In the vasculature, PAR 2 has many effects that are proinflammatory. Agonists of PAR 2 induce relaxation in the rings of rat aorta or porcine coronary artery dependent on endothelial NO synthase activity (246, 248, 250) . This effect is abolished in the absence of endothelium (246, 250) . In contrast, trypsin stimulates contraction of the rabbit aorta in the absence of endothelium (264) . In the intact rat, iv injection of SLIGRL-NH 2 produces a marked fall in blood pressure, consistent with release of NO from endothelial cells (248) . Furthermore, PAR 2 agonists increase IL-6 production (72), induce von Willebrand factor release, and serve as a mitogen for human umbilical vein endothelial cells (HUVEC) (97, 265, 266) .
Moreover, it was demonstrated that some inflammatory mediators are able to affect the expression of PAR 2 in endothelial cells. In HUVEC, PAR 2 mRNA is up-regulated by TNF-␣ and IL-1␣, cytokines that act together to orchestrate the acute inflammatory response (25, 265) .
In summary, PAR 2 mediates vasodilation, plasma protein extravasation, as well as endothelial cell proliferation in the cardiovascular system. Thus, this receptor can be regarded as an important factor in neovascularization. Moreover, PAR 2 can be considered as a vascular sensor for trypsin-like proteinases of the coagulation cascade, which play an important role in cardiovascular medicine.
B. Immune cells
Although information has been acquired about the role of PAR 2 in epithelial and endothelial function, relatively little is known so far about the role of this receptor in the immune system. As was recently demonstrated, PAR 2 is expressed by various cells involved in immune response, such as T cell lines, eosinophils, neutrophils, and mast cells (147, 160, 249, 252, 267). Accumulating evidence points to a role of PAR 2 in the regulation of leukocyte function. Some of the PAR 2 -mediated effects on leukocyte behavior have been observed in vivo in rodents (262) . In this model, it has been reported that the PAR 2 -AP (SLIGRL-NH 2 ) caused a significant increase in leukocyte migration into the peritoneal cavity after ip injection. Furthermore, PAR 2 -APs induced a significant increase in leukocyte rolling and adherence by a mechanism depending on the release of platelet-activating factor (262). Lindner et al. (268) have also demonstrated the importance of PAR 2 for leukocyte adhesion and rolling. In a model of acute inflammation induced by tissue trauma, they showed that PAR 2 -deficient mice have a decreased leukocyte rolling capacity compared with wild-type mice. Conversely, activation of PAR 2 by a specific PAR 2 -AP in wild-type mice induced a significant reduction of leukocyte rolling velocity, an increased leukocyte rolling flux as well as increased leukocyte adhesion (268) .
Howells et al. (252) reported that a specific PAR 2 -AP as well as trypsin are able to activate PAR 2 on human neutrophils. PAR 2 activation caused shape changes and up-regulation of CD11b/CD18 in these cells. In a coculture of human neutrophils with endothelial cells, PAR 2 agonists induced L-selectin shedding and CD11b/CD18 up-regulation in neutrophils (268) . We demonstrated that PAR 2 agonists induce [Ca 2ϩ ] i release in human neutrophils and enhance neutrophil motility in 3-D collagen gel lattices (269) . Moreover, Lourbakos et al. (27) demonstrated that a bacterial proteinase, gingipain-R from P. gingivalis, activates PAR 2 on human neutrophils. Because many bacteria with pathogenicity in humans produce serine proteinases with trypsin-like activity, it can be assumed that certain pathogenic effects of bacteria in many tissues can be mediated through PAR 2 . For example, Lourbakos et al. (28) reported that activation of PAR 2 by bacterial gingipain R leads to IL-6 secretion in human oral epithelial cells. In mouse airways, PAR 2 agonists were capable of inhibiting the recruitment of neutrophils induced by bacterial proteinase (270) , suggesting a direct role of PAR 2 on neutrophil function in vivo. From these data, one may speculate that PAR 2 may serve as a receptor for serine proteinases derived from bacteria, viruses, or even fungi and may thus directly trigger inflammatory or immune responses in vivo induced by microorganisms. However, this intriguing hypothesis remains to be verified.
Recent work has shed some light on the role of PAR 2 on eosinophil function. Miike et al. (267) clearly demonstrated that human eosinophils express functional PAR 2 . Furthermore, trypsin as well as a specific PAR 2 -AP was able to induce degranulation and superoxide production in human eosinophils. More recently, Temkin et al. (79) reported that human mast cell tryptase induced up-regulation of IL-8 mRNA and caused IL-8 release from human eosinophils. A comparable effect of tryptase on eosinophil IL-6 expression and release was also observed. This effect of tryptase appears to be activated via the protein kinase/AP-1 signaling pathway (79). Schmidlin et al. (271) have also demonstrated that PAR 2 mediates infiltration of eosinophils and hyperreactivity in allergic inflammation of the airway. Furthermore, PAR 2 activation releases survival factors such as granulocytemacrophage colony-stimulating factor (GM-CSF) from eosinophils (272) . Together, these results are clearly in favor of an important role of PAR 2 in eosinophil regulation and in inflammatory/allergic diseases in which eosinophils are involved.
Several T cell lines also express PAR 2 (244) . Trypsin as well as a synthetic PAR 2 -AP induce [Ca 2ϩ ] i mobilization in the Jurkat and HPB.ALL T cell lines (249) . In Jurkat cells, the involvement of PARs, possibly PAR 2 , in Vav1-mediated signaling was clearly demonstrated (236) .
The localization of PAR 1 and PAR 2 on human mast cells was first reported by D'Andrea et al. (147) . As shown by immunohistochemistry, PAR 2 was localized not only on the cell membrane of mast cells, but also on the membrane of the intracellular tryptase-positive granules (147). Moreover, rat peritoneal mast cells also express PAR 2 mRNA (273). However, the precise role of PAR 2 in mast cells especially with regard to a potential autocrine regulatory mechanism via tryptase activation requires additional investigation. In summary, these results provide evidence for a role of serine proteinases in directly regulating immune cells and immune responses via PARs. An understanding of the molecular mechanisms by which PAR 2 is involved in immune regulation will aid the design of new antiinflammatory drugs that can target proteinase-activated receptors.
C. Arthritis
Arthritis is a chronic inflammatory disease that is characterized by joint swelling, vasodilatation, edema, hyperemia, pain, and recruitment of inflammatory cells, especially neutrophils and macrophages, but also lymphocytes. Very recently, it was demonstrated that PAR 2 participates in the pathophysiology of arthritis (274) . Using PAR 2 -deficient mice, the authors showed that PAR 2 deficiency results in a marked reduction of swelling responses of experimentally induced monoarthritis. However, no differences were observed concerning joint damage when compared with wildtype mice. Using an enzymatic approach (␤-galactosidase), they also showed positive ␤-gal staining in endothelial cells of blood vessels. Two weeks after induction of monoarthritis, however, a significant increase of ␤-gal staining of extravascular inflammatory cells was observed in PAR 2 ϩ/ϩ mice compared with PAR 2 Ϫ/Ϫ mice. Examination of the knee joint showed dramatic arthritic changes in PAR 2 ϩ/ϩ mice characterized by synovial hyperplasia, an enhanced inflammatory infiltrate, and cartilage damage. Thirty days after the induction of monoarthritis, the cartilage was completely replaced by pannus in PAR 2 ϩ/ϩ mice. (247, 275, 276) . In humans, PAR 2 is also expressed by dermal immunocompetent cells, which so far have not been characterized (24) , and by dermal sensory nerves (277) . Potential endogenous activators of PAR 2 in human skin are mast cell tryptase, proteinases of the trypsin-family produced by keratinocytes (trypsinogen-4), and proteinases of the fibrinolysis cascade, such as factor VII/Xa, which could be released during inflammation and wound healing. Exogenous activators of PAR 2 may be serine proteinases generated by bacteria, fungi, and house dust mites, although direct evidence on keratinocytes is still lacking. Indirect evidence for bacterial-induced activation of PAR 2 is coming from the observation that bacterial gingipain activates the receptor on buccal keratinocytes (28) . At certain stages of atopic dermatitis or psoriasis, mast cells are in close contact to basal keratinocytes or are recruited into the epidermal layer (278) . Numerous mast cells are found in the dermis in close proximity to blood vessels and at the dermal-epidermal border in atopic dermatitis and psoriasis. Thus, tryptase or other skinderived proteinases may activate PAR 2 to induce inflammatory changes and thereby contribute to the pathophysiology of atopic dermatitis and psoriasis. It is well known that intradermal injection of tryptase into the skin results in vasodilatation and erythema, followed by leukocyte infiltration and local induration (279) , indicating a role of tryptase in cutaneous inflammation. Moreover, tryptase is an important long-term marker in body fluids for systemic anaphylaxis and other immediate hypersensitivity allergic reactions (280) . Thus, it is possible that PAR 2 mediates the systemic effects of tryptase in certain skin diseases.
Serine proteinases other than tryptase may also activate PAR 2 . Cytotoxic T cells, which express PAR 2 (249), also produce the trypsin-like enzyme granzyme A (281), suggesting a potential role for PAR 2 in regulating T cells in inflammatory dermatoses. In summary, proteinases in the skin are signaling molecules that may directly regulate the function of target cells by activating PAR 2 . PAR 2 as well as PAR 1 agonists regulate cytokine production such as IL-8 (282), IL-6, and GM-CSF (283) in cultured human keratinocytes. Furthermore, PAR 2 may also regulate proliferation and differentiation in the skin. Similar to TGF-␤, PAR 2 agonists inhibit proliferation or differentiation of human neonatal keratinocytes, whereas PAR 1 agonists stimulate proliferation (275) . In contrast, agonists of both PAR 2 and PAR 1 are mitogenic for endothelial cells (248) . Thus, our observations in normal and inflamed human skin suggest a functional role of PAR 2 in different cell types of human skin during inflammation.
In human skin, PAR 2 is only weakly expressed by microvascular endothelial cells. Studies done in vitro revealed that PAR 2 is functionally expressed by human dermal microvascular endothelial cells and that PAR 2 agonists induce up-regulation and release of IL-6 and IL-8 in a concentrationdependent fashion (263) . Moreover, PAR 2 regulates expression of cell adhesion molecules in primary cultures of human endothelial cells (284) and cell lines (268) . These findings are supported by in vivo findings demonstrating a role of PAR 2 in the adhesion, rolling, and extravasation of leukocytes in rat venules. Finally, PAR 2 appears to play a role in the regulation of leukocyte/endothelial interactions in humans and mice in vivo, as shown for atopic dermatitis or experimentally induced contact dermatitis (285) . Together, these results strongly support the idea that PAR 2 plays an important role in leukocyte/endothelial interactions during inflammation and immune response.
The knowledge about the signaling cascades involved in PAR 2 -induced inflammatory and immune responses by keratinocytes is still incomplete. Recently, Kanke et al. (286) have shown that PAR 2 agonists stimulate activation of inhibitory B kinases (IKK)␣ and IKK␤, and also stimulate NFB-DNA binding. Our own data using primary human keratinocytes also clearly demonstrate that PAR 2 activates NFB (287).
Moreover, PAR 2 is directly involved in the NFB-mediated regulation of keratinocyte ICAM-1, which is an important molecule for the regulation of keratinocyte immune responses such as host defense, allergy, and recruitment of inflammatory cells into the epidermis (287) .
Finally, recent data suggest a role of PAR 2 during cutaneous inflammation in vivo. In a murine model of experimentally induced allergic contact dermatitis, a proinflammatory role of PAR 2 agonists was demonstrated (285, 288) . Stimulation of PAR 2 resulted in increased ear swelling responses with a maximum after 48 h. Independently, our group confirmed the proinflammatory effects of PAR 2 agonists in a model of experimentally induced allergic and irritant contact dermatitis using PAR 2 -deficient mice. Moreover, we examined the underlying mechanisms responsible for PAR 2 -induced effects during contact dermatitis (285) . These results clearly indicate that PAR 2 is involved in edema formation, plasma extravasation, up-regulation of cytokines (IL-6), cell adhesion molecules (ICAM-1), and selectins (Eselectin) in mice. Intravital microscopy studies further showed that velocity and adhesion of leukocytes is impaired in PAR 2 -deficient mice compared with controls. Moreover, in vivo studies by microdialysis confirmed a role of PAR 2 in mediating vascular responses such as edema formation and plasma extravasation also in human skin. Finally, ex vivo studies in skin biopsies of human volunteers are in favor of a role for PAR 2 in selectin regulation of dermal blood vessels because PAR 2 agonists induced a marked increase of Eselectin immunoreactivity in dermal endothelial cells in comparison to control tissues. Together, these results support a regulatory role of PAR 2 during cutaneous inflammation and immune response.
E. Airways
Several observations are in favor of an important role of PAR 2 in airway inflammation. Firstly, tryptase (251, 289) seems to play an important role in airway inflammation and hyperresponsiveness (253) . Secondly, PAR 2 is markedly upregulated after exposure to proinflammatory stimuli or cytokines (265) that have been shown to play a role in chronic airway diseases. Morphological studies have demonstrated PAR 2 immunoreactivity in endothelium and smooth muscle of bronchial vessels. These observations are consistent with a similar distribution in other tissues and with the known ability of PAR 2 agonists to cause arterial relaxation as well as contraction in certain arteries (290) . Moreover, PAR 2 is expressed by bronchial, tracheal, epithelial and SMC which may result in direct or indirect bronchomotor effects leading to pathophysiological conditions in the airways such as asthma or chronic obstructive pulmonary disease. Interestingly, PAR 2 agonists are capable of causing bronchoconstriction (291) . Whether this response is dependent on secondary effects such as the generation of bronchoactive peptides or other mediators remains to be determined. However, studies done in vitro suggest further that PAR 2 agonists also produce a relaxant effect in isolated main bronchi (292) . Thus, PAR 2 agonists may cause dose-dependent bronchoconstrictor or bronchodilatator effects in the airways, with high agonist concentrations favoring bronchoconstriction. NO and prostanoids like PGE 2 may be involved in this process, because potentiation of PAR 2 -induced bronchoconstriction has been observed upon inhibiting NO synthase or after prostanoid generation and COX-2 activation (153). In conclusion, there is strong evidence that PAR 2 stimulation activates contractile and dilator mechanisms in the airways. The reason why the predominant effect in guinea pig airways in vivo is bronchoconstriction, however, is not known at present. In addition to the potentially bronchoprotective effects observed by Cocks et al. (292) in rat bronchial preparations, others have shown that PAR 2 may also mediate bronchoprotection in guinea pig airways (293) . However, other observations show that PAR 2 can act as an enhancer of histamine-mediated contraction (294) . The study of Cocks et al. (292) showed that trypsin colocalized with PAR 2 in airway epithelial cells, where PAR 2 activation resulted in relaxation of airway preparations by the release of cytoprotective PGE 2 . Prostanoids may be important mediators of PAR 2 activity in the airways not only in the lung, but also in the GI tract (152, 153, 253, 295) . It is tempting to speculate that tryptase and/or other proteinases with trypsin-like activity, released in close proximity to the cells expressing PAR 2 , may stimulate this receptor during airway inflammation. Finally, intensive staining of PAR 2 in the apical region of the airway epithelium might suggest an activating role of proteinases, for instance bacterial proteinases, present in the airway lumen (296) . Very recently, PAR 2 was shown to stimulate the release of MMP-9 in a human epithelial cell line (297) , providing a strong hint that PAR 2 is involved in the orchestration and reorganization of lung extracellular matrix proteins.
It was also revealed that PAR 2 stimulation of airway epithelial cells leads to the release of eosinophil survival-promoting factors such as GM-CSF (272) . Moreover, in human respiratory epithelial cells, PAR 2 , like PAR 1 , stimulates IL-6, IL-8, and PGE 2 release (77).
Profound evidence for an involvement of PAR 2 in allergic inflammation of the airways is provided by the recent work of Schmidlin et al. (271) . To study the involvement of PAR 2 in airway inflammation, they used PAR 2 -deficient mice and mice overexpressing human PAR 2 (PAR 2 tg). PAR 2 is known to be up-regulated by inflammatory agents. Sensitization of wild-type mice by injection of ovalbumin led to infiltration of immune cells into the lumen of the airways and induced hyperreactivity, whereas both infiltration of eosinophils into the lumen and airway hyperreactivity was exacerbated in PAR 2 tg mice. In contrast, infiltration of immune cells and airway hyperreactivity was markedly diminished in PAR 2 -deficient mice. Additionally, in PAR 2 Ϫ/Ϫ mice the IgE response was strongly reduced, implicating a role of PAR 2 in immune response. Remarkably, intranasal administration of PAR 2 -AP in wild-type mice stimulated increased recruitment of macrophages, confirming the proinflammatory role of PAR 2 in the airways, whereas altered PAR 2 expression mainly influenced eosinophil infiltration.
In summary, evidence exists for a proinflammatory as well as antiinflammatory role of PAR 2 in airway inflammation. This dual role may be explained by the various tissues, cells, methodological approaches, and inflammatory model systems (acute vs. chronic, mouse strains) that have been used to evaluate this role of PAR 2 in the airways. So far, it appears that PAR 2 is a sensor receptor that releases proinflammatory mediators in the early phase and antiinflammatory molecules in the late phase of "regulated inflammation." Under "dysregulated" inflammatory situations such as chronic disease states, PAR 2 may exert antiinflammatory effects, as shown in a colitis model (298) , or proinflammatory effects, as demonstrated in an asthma model (271) . Thus, additional studies using human and mouse (knockout) models of pulmonary dysfunction are necessary to fully explain the role of PAR 2 during inflammation and immune response.
F. Brain and peripheral nervous system
By immunohistochemistry, PAR 2 has been localized in various compartments of the nervous system such as brain, spinal cord, DRG, and peripheral nerves, with different receptor densities found during various stages of mouse development (299) . At d 14, PAR 2 -staining was observed throughout the mouse brain. Among the hippocampal formation, PAR 2 was localized in the subiculum, in pyramidal cells throughout the CA1, CA2, CA3, and hilus region, and in granular cells of the dentate area. Additionally, staining for PAR 2 was observed in all cortical layers, amygdaloid nuclei, striatum, thalamus, and hypothalamus (175). Peripheral nerves were intensively stained after d 14. Similarly, PAR 2 has also been detected in human brain (276) . In rat brain, PAR 2 is also expressed by neurons of the hippocampus (175, 300), meningeal cells (301), as well as astrocytes (176, 185). PAR 2 is abundantly expressed in various subareas and is transiently up-regulated during oxygen and glucose deprivation (175). Moreover, PAR 2 activation is cytotoxic for isolated rat hippocampal neurons in a concentration-dependent manner (300).
Domotor et al. (302) recently reported that agonists of PAR 2 induce Ca 2ϩ responses in brain microvascular endothelial cells. This effect may be modulated by elastase and plasmin, which regulate PAR 2 signaling. Studies of the actions of PAR 2 agonists on CNS targets suggest an important role of PAR 2 during injury, growth, apoptosis, and probably memory.
Very recently, PAR 2 has been localized on rat sensory neurons (243) . Moreover, functional data strongly support the idea that the peripheral nervous system is directly regulated by PAR 2 during neurogenic inflammation. Neuropeptides such as calcitonin gene-related peptide and substance P (SP) from primary spinal afferent neurons are known as important mediators of neurogenic inflammation in many organs. Because of the close proximity of tryptase-containing mast cells to spinal afferent fibers, and because agonists of PAR 2 cause effects similar to those of tryptase in many tissues, comprising many of the characteristics of neurogenic inflammation, it was speculated that serine proteinases or other PAR 2 agonists may activate PAR 2 on sensory neurons to stimulate neuropeptide release and may thus regulate inflammation. Indeed, it was shown that agonists of PAR 2 can induce inflammation by a neurogenic mechanism that depends on the release of calcitonin-gene related peptide (CGRP) and SP from primary spinal afferent neurons. However, there also appears to be a nonneurogenic component of PAR 2 -induced inflammation because granulocyte infiltration triggered by PAR 2 in a paw edema inflammation model was unaffected by sensory denervation or by neuropeptide receptor antagonists. Thus, PAR 2 agonists may also act directly on endothelial cells or on neutrophils themselves to stimulate inflammation-related granulocyte adhesion and infiltration (14, 250) . It is possible that serine proteinases may activate PAR 2 on spinal afferent neurons under pathophysiological inflammatory circumstances. In a similar manner, serine proteinases may regulate enteric neuronal function by cleaving PAR 2 in a Ca 2ϩ -dependent manner (196) . Trypsin, which is released by airway epithelial cells, but not the PAR 2 agonist peptide sequence SLIGRL, induced a marked contraction in guinea pig bronchi via SP release. Thus, non-PAR mediated effects of trypsin may also regulate neuropeptide function in the lung (303) .
Several reports strongly suggest a role of PAR 2 in the central transmission of pain and nociception in rats and mice (304 -306) . Intraplantar administration of low doses of PAR 2 agonists, which do not induce inflammation, resulted in a long-lasting hyperalgesia. Interestingly, these effects of PAR 1 agonists were more efficacious in comparison with other inducers of hyperalgesia such as PGE 2 (0.3 g). In the spinal cord, PAR 2 agonists induced an up-regulation of c-fos, a marker of activated nociceptive neurons (305, 307, 308 ). Another study also reported a role of PAR 2 in a rat visceral pain model (308) . PAR 2 agonists administered in vivo clearly increased abdominal colonic contractions. This effect was inhibited by an NK 1 receptor antagonist, but not by the PG inhibitor indomethacin (308) . However, additional studies are necessary to fully explain the underlying direct or indirect effects of PAR 2 -induced nociception. For example, neuropeptides released from neurons upon PAR 2 stimulation may activate the release of nociceptive mast cell mediators such as kinins or prostanoids (309) .
The observation that PAR 2 agonists are involved in the transmission of neurogenic inflammation and pain subsequently draws the question whether PAR 2 may be involved in the central transmission of pruritus. Itching is one of the most frequent symptoms in dermatological diseases and accompanies inflammatory and immune responses of many diseases such as hypersensitivity reactions or urticaria, for example. Indeed, neuronal PAR 2 appears to be involved in the induction of pruritus in human skin (277) . Moreover, the endogenous PAR 2 agonist tryptase was increased up to 4-fold in atopic dermatitis patients, and PAR 2 expression was markedly enhanced on primary afferent nerve fibers in skin biopsies of atopic dermatitis patients. Intracutaneous injection of specific PAR 2 agonists provoked enhanced and prolonged itch when applied intralesionally. Thus, PAR 2 activation on cutaneous sensory nerves may be a novel pathway for the transmission of itch and inflammatory responses during atopic dermatitis and probably other skin diseases. PAR 2 antagonists may be promising therapeutic targets for the treatment of cutaneous neurogenic inflammation and pruritus (277) .
In summary, PAR 2 may play an important regulatory role in the central and peripheral nervous system in normal and disease states, including neurogenic inflammation.
G. Digestive tract and pancreas
In rats, Kawabata et al. (167, 310, 311) detected PAR 2 mRNA in the sublingual, submaxillary, and parotid salivary glands. Of these three distinct salivary glands, the sublingual exhibited the strongest responses to PAR 2 activation resulting in the secretion of mucin. This response appeared to be mediated in part via a tyrosine kinase signal pathway, because genistein, an inhibitor of several tyrosine and other protein kinases, attenuated the effect. Pretreatment with the alkaloid capsaicin, which activates the transient receptor potential of vanilloid type 1 and which, in turn, is known to play a major role in inflammatory thermal nociception, failed to abrogate the secretion of mucin from salivary glands but abolished the PAR 2 -triggered cytoprotective secretion of mucus in the stomach. These results provide both a sensory neuron-independent and -dependent mechanism for PAR 2 -regulated exocrine secretion (312) . Additional support for a role of PAR 2 in salivary gland secretion was provided by data showing that a PAR 2 agonist can stimulate amylase secretion from rat parotid gland slices in vitro (311) .
In the GI tract, PAR 2 is highly expressed by enterocytes, where it is localized on the apical and basolateral membranes (253, 313) . Moreover, myocytes of the muscularis mucosae and muscularis externa as well as neuronal elements are immunoreactive for PAR 2 . Recent observations indicate that trypsin may regulate enterocytes by cleaving and triggering PAR 2 at the apical membrane (253) to induce the generation of PGE 2 and PGF 1a , suggesting that PAR 2 may have a cytoprotective as well as an inflammatory effect on the GI tract. Moreover, mucosal mast cell proteinases may possibly activate PAR 2 on enterocytes and colonic myocytes. PAR 2 -mediated inhibition of intestinal motility may contribute to inflammatory conditions in which mast cells are involved.
Trypsin may activate PAR 2 in the pancreas itself under physiological and pathophysiological conditions because trypsin can be prematurely activated in the inflamed pancreas (314). PAR 2 seems to play an important role also in pancreatic nociception because injection of an AP specific for PAR 2 can activate and sensitize pancreas-specific afferent neurons in vivo (314) . Moreover, Hoogerwerf et al. (314) found that stimulating DRG with a PAR 2 -AP resulted in enhanced capsaicinand KCl-stimulated release of calcitonin gene-related peptide, which is a marker for nociceptive signaling. PAR 2 is expressed by both acinar cells, which release digestive enzymes, and duct cells, which produce fluid and bicarbonate. In isolated pancreatic acini, trypsin and PAR 2 agonists stimulate amylase release (154) (N. W. Bunnett, personal communication). In vivo studies revealed the secretion of pancreatic juice after PAR 2 activation (167). Interestingly, PAR 2 agonists applied to the basolateral but not apical membrane of monolayers of pancreatic duct cells increase short circuit currents due to activation of Ca 2ϩ -sensitive Cl Ϫ and K ϩ channels (315) . These effects may be of relevance in pancreatitis when trypsin is released across the basolateral membrane.
H. Signaling by proteinases via PAR 2
There are relatively few studies examining the involvement of PAR 2 in signaling cascades compared with the relatively large number of studies concerning PAR 1 -mediated intracellular signaling (13, 14) . So far, there are only indirect data indicating that PAR 2 interacts with G q /G 11 (activation of calcium signaling) and possibly with G 0 /G i (316) . Whether or not PAR 2 binds to other G proteins, such as G 12 or G 13 , remains unclear.
Interaction of PAR 2 with G i and G q suggests a subsequent activation of PLC, PKC, and MAPK pathways. These signaling pathways can affect various cell activities including cell proliferation, morphological changes, motility and survival, and gene transcription regulation (Table 2 and Fig. 3) . Indeed, as demonstrated for neuronal cells and SMC, stimulation by tryptase as well as PAR 2 -AP leads to subsequent activation of PLC and PKC (317, 318) . Kanke et al. (286) demonstrated that PAR 2 agonists (trypsin as well as the AP SLIGKV-NH 2 ) stimulate JNK and p38 MAPK activation in a human keratinocyte cell line (NCTC2544). Moreover, Vouret-Craviari et al. (225) described PAR 2 -induced activation of RhoA in HUVEC revealing a possible mechanism underlying PAR 2 -mediated effects at cytoskeleton in macrovascular endothelial cells. Together, these data shed some light on the potential signaling mechanisms underlying PAR 2 -associated cellular effects such as depolarization response in neuronal cells, proliferation and mitogenic response in SMC, proliferation and differentiation of keratinocytes, and cytoskeletal changes in endothelial cells (225, 275, 319, 320) .
Additionally, the effects of trypsin as well as PAR 2 -AP on the activation of nuclear transcriptional factors have recently been demonstrated. It was shown that PAR 2 agonists stimulate NFB-DNA binding activity and activation of upstream kinases IKK␣ and IKK␤ (286) . The effects of PAR 2 stimulation on NFB or IKK also have been described in other studies performed on different cell types (13, 263, 287, 297, 321) .
It is also important to pay attention to factor Xa signaling mediated via PAR 2 . It was mentioned in Section II.H.6 that this factor induces signaling events via PAR 1 ; the potential role of PAR 2 in such signaling remained unclear for a long time. Recently, however, the involvement of PAR 2 activation in coagulation factor Xa signaling has been reported. In HUVEC, factor Xa interacts with a protein called effector cell proteinase receptor-1 (EPR-1). This interaction is associated with signal transduction, generation of intracellular second messengers, and modulation of cytokine gene expression. Inhibitors of factor Xa blocked these responses (322) . Additionally, direct cleavage of PAR 2 by factor Xa has been demonstrated, reflecting the complexity of PAR 2 -induced signaling. These data allowed the authors to suggest that factor Xa induces endothelial cell activation via a novel cascade of receptor activation involving docking to EPR-1 and proteolytic cleavage of PAR 2 (322) .
As already mentioned extensively in Section II.H, PAR 1 and PAR 2 both account for around 90% of endothelial factor Xa-mediated signaling in mice. In contrast, PAR 1 virtually accounts for all factor Xa-induced activation in fibroblasts, indicating potential cell-specific synergistic effects of PAR receptors on target cells (25) .
Moreover, Koo et al. (323) demonstrated an involvement of PAR 2 in factor Xa signaling by analyzing factor Xa-induced stimulation of coronary artery SMC using cell proliferation and ERK1/2 activation as indices of response. Furthermore, factor Xa-induced ERK1/2 activation was not desensitized by preincubation of the cells with thrombin. However, ERK1/2 activation was markedly attenuated by prior exposure of the cells to PAR 2 -AP (SLIGKV-NH 2 ). The mitogenic effect of factor Xa was significantly reduced in the presence of an anti-PAR 2 monoclonal antibody that attenuates receptor activation, demonstrating the specificity of these effects (323) . Together, these observations suggest that various signaling cascades are involved in PAR 2 -mediated signaling. Clearly, we are just beginning to understand the variety of PAR 2 -induced cell signaling pathways regulated under physiological conditions and during disease.
IV. PAR 3 and PAR 4
A. Biology and distribution of PAR 3 and PAR 4 As already mentioned, murine platelets do not express PAR 1 . The observation that thrombin was still capable of inducing Ca responses in these cells led to the identification of PAR 3 (18) . In humans, PAR 3 is expressed in bone marrow, heart, brain, placenta, liver, pancreas, thymus, small intestine, stomach, lymph nodes, and trachea, although the cell types remain to be identified. In mouse, PAR 3 is expressed by megakaryocytes and platelets, among other cell types. The receptor is necessary for normal thrombin signaling in mouse platelets because blocking of the hirudin-like domain of PAR 3 using a specific antibody prevented mouse platelet activation by low but not by high concentrations of thrombin. The same result was observed with PAR 3 -deficient platelets (19, 324) . This also shows that PAR 3 is a high-affinity thrombin receptor in mouse that is activated by proteolytic cleavage. Interestingly, murine PAR 3 (mPAR 3 ) itself does not lead to thrombin signaling even when overexpressed, indicating that the receptor has lost its ability to function autonomously during evolution (39, 40) . Knocking out the PAR3 gene in mice leads to protection of the animals against thrombosis but has a relatively mild effect on hemostasis (325) ( Table 2) . However, analysis of PAR 3 expression in human platelets Table 2 ).
showed that the receptor is not produced or is hardly produced by these cells (128). This suggests that in humans PAR 3 does not play a major role for platelet activation in contrast to the mouse system.
Antibodies specific for PAR 1 inhibited human platelet activation by low but not by high concentrations of thrombin (125, 326) . In mice, PAR 3 is necessary for normal thrombin signaling in platelets. This indicates the presence of more than one thrombin receptor on the surface of these cells. Indeed, a fourth receptor was cloned, named PAR 4 (19, 20, 128) . So far, PAR 4 has been cloned from human, mouse, and rat tissues (19, 20, 327) . In humans, PAR 4 is widely expressed in brain (175), testes, placenta, lung, liver, pancreas, thyroid, skeletal muscle, and small intestine (20) . In rats, PAR 4 is expressed in esophagus, stomach, duodenum, jejunum, distal colon, spleen, and brain (327, 328) .
Both in mice and humans, platelets utilize two thrombin receptors. PAR 4 is a low-affinity receptor in platelets both in humans and mice. However, mouse platelets use PAR 3 and PAR 4 instead of PAR 1 and PAR 4 to respond to thrombin (19) . In humans, platelet effects of thrombin appear to be mediated predominantly by PAR 1 . Only at high concentrations and when PAR 1 activation has been inhibited is platelet activation by thrombin dependent on PAR 4 . Signals mediated by PAR 4 result in calcium influx (19, 122, 329) , thromboxane production (117), endostatin secretion in rat platelets (118), and platelet aggregation (122) ( Table 2 ). However, selective activation of human PAR 4 (hPAR 4 ) resulted in a weaker response compared with hPAR 1 -mediated signaling because anionic phospholipids were not exposed on the surface of hPAR 4 -activated platelets. Interestingly, hPAR 4 can also be activated by cathepsin G, a neutrophil granule proteinase (330) . Cathepsin G mediates neutrophil-platelet interactions at sites of vascular injury or inflammation. Inhibition of hPAR 1 had no effect on platelet responses to cathepsin G, indicating a specific activation of PAR 4 .
Patients with Hermansky-Pudlak syndrome, an autosomal recessive disorder, lack platelet dense granules and have no ADP autocrine response. However, these patients show only a mild bleeding phenotype (331, 332) . It was hypothesized that the defect of ADP autocrine response was compensated by signaling through PAR 4 because the activation of this receptor occurs well after ADP release in normal individuals (333) . Therefore, the ADP-autocrine response does not seem to be necessary for platelet aggregation as long as PAR 4 is strongly activated. However, it was observed by another laboratory that PAR 4 -induced, but not PAR 1 -induced, aggregation was entirely ADP-dependent using a specific AP for PAR 4 (334) . Moreover, the authors found that subthreshold concentrations of an APactivating PAR 1 potentiated the effects of a PAR 4 -AP to stimulate maximal aggregation. In addition, both prostacyclin (PGI 2 ) and S-nitroso-glutathione, an NO-releasing agent, reduced AP-stimulated aggregation and fibrinogen-receptor up-regulation.
PAR 4 Ϫ/Ϫ mice had markedly increased bleeding times (40) . In addition, the platelets of these mice failed to change shape, mobilize calcium, or aggregate in response to thrombin. Ma et al. (118) observed that a specific AP for PAR 4 could induce endostatin release in rat platelets. A selective PAR 4 antagonist prevented endostatin release. In human platelets, specific agonists for PAR 1 or PAR 4 stimulated thromboxane production (117). Thromboxane produced by the combined stimulation of PAR 1 and PAR 4 was additive, suggesting the presence of two pathways for thrombin-induced thromboxane production in platelets. Blocking PAR 1 function with a domain-specific antibody resulted in substantial inhibition of thrombin signaling. However, PAR 4 can mediate platelet activation in response to high concentrations of thrombin (128). hPAR 4 itself showed no pharmacological effect at either 1 nm or 30 nm thrombin. However, blocking of both hPAR 1 and hPAR 4 resulted in a profound inhibitory response even at high concentrations of the proteinase (128). This shows that hPAR 4 activation is not necessary for robust responses in platelets when hPAR 1 function is intact. Thus, inhibition of hPAR 1 alone is probably not sufficient when seeking new antithrombotic therapies; it might be necessary to block both receptors simultaneously (106, 128) . hPAR 4 seems to play a role as a backup signaling device that might mediate thrombin signaling to distinct effectors or with different kinetics compared with PAR 1 . It might also allow platelets to respond to proteinases other than thrombin. Moreover, both receptors might be able to directly interact with each other.
The fact that mPAR 3 alone does not result in thrombin signaling on mouse platelets showed that mPAR 3 functions as a cofactor that promotes cleavage and activation of PAR 4 at low concentrations of thrombin (39, 40). Interestingly, knocking out the PAR 3 or the PAR 4 gene leads to a similar degree of protection against thrombosis in mice (40, 325). In humans, both hPAR 1 and hPAR 4 may independently mediate thrombin signaling (20, 128, 177) . Thus, the mouse system does not have a direct analog in the human platelet. However, mPAR 3 promoted cleavage and activation of hPAR 4 as effectively as mPAR 4 . Thus, hPAR 4 can be "cofactored" by PAR 3 in vitro, but it remains unclear whether or not cofactors such as PAR 1 play a direct role in hPAR 4 activation in vivo (39).
This reservoir of multiple thrombin receptors including PAR 1 , PAR 3 , and PAR 4 may allow for a precise regulation of thrombin-induced inflammatory stimuli under different pathophysiological conditions and the fine-tuned induction of different signal transduction pathways.
In endothelial cells, thrombin induces a rapid but transient activation of endothelial cells by stimulating the secretion of PGI 2 or platelet-activating factor (PAF) and by inducing the production of cell adhesion molecules (P-selectin, E-selectin) (47, 69, 70). Thrombin and a nonselective AP also induce synthesis and release of cytokines from endothelial cells such as IL-1, IL-6, and IL-8 (71, 72). Moreover, they regulate the cytokine-independent expression of ICAM-1 and VCAM-1 on human endothelial cells and cause an increased adhesion of monocytes to endothelial cells. This effect can be diminished by blocking antibodies (anti-CD 18, anti-CD 49d) (73). In the past, the effects observed above had been attributed to the activation of PAR 1 . However, a recent in vivo study has shown that thrombin-induced leukocyte rolling and adhesion to vascular walls is mediated via PAR 4 (74). Although thrombin can trigger the recruitment of leukocytes to sites of inflammation, the PAR 1 antagonist RWJ-56110 does not block this effect. In contrast, a PAR 4 -AP is able to reproduce the effects of thrombin on leukocyte rolling and adherence, indicating that this proinflammatory effect of thrombin is due to the activation of PAR 4 and not PAR 1 (74). Thus, PAR 4 appears to function in early events of inflammatory reaction, in terms of recruiting leukocytes to the site of injury.
In contrast to a potential participation of PAR 1 in stimulating the angiogenic process (335), PAR 4 may play an opposing role. Apart from its antiangiogenic role via the activation of platelets, PAR 4 can also affect the arterial system by stimulating vascular smooth muscle mitogenesis (220) .
PAR 4 , like PAR 1 and PAR 2 , also appears to be linked to signal transduction processes that modulate airway smooth muscle tone, because a PAR 4 -AP caused a rapid transient contractile response in a murine tracheal preparation. This contraction was followed by a transient relaxant phase. The underlying molecular mechanism is still unclear, but the relaxation appears to be dependent on PAR 4 -stimulated and COX-2-generated PGE 2 production, which activates the Etype prostanoid 2 receptor (152, 153).
In conclusion, preliminary data strongly suggest an important pathophysiological role of PAR 4 in vascular homeostasis and platelet function. However, the role of PAR 3 as a signaling molecule and the precise function of PAR 4 during inflammation and immune response remain to be clarified.
B. Signaling by proteinases via PAR 3 and PAR 4
PAR 3 and PAR 4 are the most recent members of the proteinase-activated receptor family. They are activated by thrombin. Subsequent to the cloning of PAR 3 (18) and PAR 4 (19, 20) , relatively few publications have appeared examining the involvement of these receptors in signaling cascades. One puzzle that is yet to be resolved, as already mentioned, is the inability of PAR 3 to signal in response to its tethered ligand-derived peptide or to thrombin (39, 40) . Until this issue is resolved unequivocally, a meaningful discussion about PAR 3 signaling is not possible. In contrast, PAR 4 appears to be capable of activating both G 12 /G 13 and G q pathways (201, 336, 337) .
As mentioned above, PAR 4 appears to be involved in the same signaling cascades as PAR 1 in human platelets. In contrast, mouse platelets express PAR 3 4 agonist with an increased binding potency to PAR 4 , they were able to demonstrate p38 phosphorylation as well as slight activation of PLC and ERK1/2. Additionally, thrombin and PAR 4 -AP, but not PAR 1 -AP, were able to activate Src in these cells, clearly indicating that the action of thrombin on Src activation is mediated by PAR 4 , and not by PAR 1 in these cells. Further studies implicated the involvement of Src and EGFR kinase activity in the PAR 4 -dependent p38 signaling pathway (338) .
Recently, the involvement of PAR 4 in factor Xa-mediated signaling has been demonstrated. Camerer et al. (25) revealed that expression of PAR 1 , PAR 2 , and PAR 4 in Xenopus oocytes confers calcium signaling in response to factor Xa. They further showed that PAR 4 -AP (AYPGKF-NH 2 ) stimulated increased phosphoinositide hydrolysis in endothelial cells and that responses to AYPGKF-NH 2 are absent in PAR 4 Ϫ/Ϫ endothelial cells (240) . Accordingly, PAR 4 -mediated phosphoinositide hydrolysis in response to factor Xa has been clearly demonstrated (25) .
V. Conclusions
There is no doubt that PARs play an important regulatory role during inflammation and immune response. Recent findings consolidate the concept that serine proteinases act as autocrine, paracrine, or endocrine mediators that talk directly to cells (13) (14) (15) 30) . Some of these proteinase-stimulated effects are mediated through activation of proteinaseactivated receptors, resulting in signal transduction pathways that are involved in inflammation and immune response. In many cases, PARs appear to play a proinflammatory role due to activation of proinflammatory mediators and cytokines (28, 59, 67, 72, 77-90, 94, 99, 263, 272, 274, 282, 283, 295, 339 -345) . In other instances, a protective and antiinflammatory role of PARs has been observed (52, 292, 298, 312, 346 -348). Various serine proteinases, which serve as PAR activators, are relevant mediators during inflammation (Table 2) . However, the precise role of PARs and serine proteinases in different tissues, cell types, and states of inflammation remains to be determined.
Open questions include: 1) For the several proteinases that are released in various tissues from different cell types during inflammation, what is their mechanism of regulation and what is their functional relevance? 2) What is the significance of the existence of multiple receptor subtypes for one proteinase, and how might these common proteinase targets be differentially regulated? 3) Which immune cells express functional PARs in humans in vivo, and what is their biological relevance? 4) Which are the endogenous proteinases that activate PAR 2 in human inflammation in vivo? 5) Which factors influence the regulation of PARs during inflammation or host defense? 6) Which effects of PAR-activating proteinases are non-PAR-mediated effects? 7) Which are the cell-specific signaling pathways and molecular mechanisms (transcription factors) after selective PAR activation in different inflammatory states and tissues? 8) What role do PARs play in neuronal transmission in humans? 9) Can PAR agonists or antagonists be used as therapeutic agents during inflammation or immune response in human diseases?
Thus, an integrative understanding of a regulatory role of serine proteinases as extracellular degradative enzymes as well as hormone-like signaling messengers in part via PARs and their counterregulation by extracellular proteinase inhibitors and intracellular molecules should lead to effective therapeutic approaches for various inflammatory/immune diseases such as thrombosis, sepsis, bacterial infections, gin- Tay 
